Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
Top Cited Papers
- 3 May 2012
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 366 (18), 1686-1695
- https://doi.org/10.1056/nejmoa1200384
Abstract
The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that among high-risk patients with aortic stenosis, the 1-year survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical replacement. However, longer-term follow-up is necessary to determine whether TAVR has prolonged benefits. At 25 centers, we randomly assigned 699 high-risk patients with severe aortic stenosis to undergo either surgical aortic-valve replacement or TAVR. All patients were followed for at least 2 years, with assessment of clinical outcomes and echocardiographic evaluation. The rates of death from any cause were similar in the TAVR and surgery groups (hazard ratio with TAVR, 0.90; 95% confidence interval [CI], 0.71 to 1.15; P=0.41) and at 2 years (Kaplan–Meier analysis) were 33.9% in the TAVR group and 35.0% in the surgery group (P=0.78). The frequency of all strokes during follow-up did not differ significantly between the two groups (hazard ratio, 1.22; 95% CI, 0.67 to 2.23; P=0.52). At 30 days, strokes were more frequent with TAVR than with surgical replacement (4.6% vs. 2.4%, P=0.12); subsequently, there were 8 additional strokes in the TAVR group and 12 in the surgery group. Improvement in valve areas was similar with TAVR and surgical replacement and was maintained for 2 years. Paravalvular regurgitation was more frequent after TAVR (P<0.001), and even mild paravalvular regurgitation was associated with increased late mortality (P<0.001). A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients. The two treatments were similar with respect to mortality, reduction in symptoms, and improved valve hemodynamics, but paravalvular regurgitation was more frequent after TAVR and was associated with increased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.)Keywords
This publication has 36 references indexed in Scilit:
- One-year interim follow-up results of the TRAVERCE trial: the initial feasibility study for trans-apical aortic-valve implantation☆European Journal of Cardio-Thoracic Surgery, 2011
- Evaluation of Patients With Severe Symptomatic Aortic Stenosis Who Do Not Undergo Aortic Valve ReplacementCirculation: Cardiovascular Quality and Outcomes, 2009
- Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patientsThe Journal of Thoracic and Cardiovascular Surgery, 2009
- 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart DiseaseCirculation, 2008
- Pulmonary Embolism in Heart FailureCirculation, 2008
- Percutaneous Transarterial Aortic Valve Replacement in Selected High-Risk Patients With Aortic StenosisCirculation, 2007
- Clinical Profile and Natural History of 453 Nonsurgically Managed Patients With Severe Aortic StenosisThe Annals of Thoracic Surgery, 2006
- Outcome of 622 Adults With Asymptomatic, Hemodynamically Significant Aortic Stenosis During Prolonged Follow-UpCirculation, 2005
- A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart DiseaseEuropean Heart Journal, 2003
- Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic StenosisCirculation, 2002